In contrast to these appealing results the phase III KEYNOTE-061 trial (n = 592) (pembrolizumab or paclitaxel) in second-line advanced GC [18] and the JAVELIN Gastric 300 phase III trial (avelumab (anti-PD-L1) or irinotecan/paclitaxel) in third-line advanced GC or GEJ cancer [19], did not result in improved overall survival (OS) but showed a more manageable safety profile than chemotherapy. This evidence concerns the gene CD274 and gastric cancer.